MRVI (Maravai LifeSciences Holdings) Cash Flow from Financing : $0.9 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, Maravai LifeSciences Holdings paid $0.0 Mil more to buy back shares than it received from issuing new shares. It spent $1.5 Mil paying down its debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $2.3 Mil on other financial activities. In all, Maravai LifeSciences Holdings earned $0.8 Mil on financial activities for the three months ended in Sep. 2024.

Maravai LifeSciences Holdings Cash Flow from Financing Historical Data

The historical data trend for Maravai LifeSciences Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Cash Flow from Financing Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

-4.17

53.21

-159.05

-187.50

-61.09

Maravai LifeSciences Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash Flow from Financing	Get a 7-Day Free Trial															0.78	0.47	-0.56	0.23	0.81

Maravai LifeSciences Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Maravai LifeSciences Holdings's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-5.772	+	0	+	0	+	-55.318
=	-61.1

Maravai LifeSciences Holdings's Cash from Financing for the quarter that ended in Sep. 2024 is:

	Cash Flow from Financing		(Q: Sep. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-1.52	+	0	+	0	+	2.329
=	0.8

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.9 Mil.

Maravai LifeSciences Holdings (NAS:MRVI) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Maravai LifeSciences Holdings's issuance of stock for the three months ended in Sep. 2024 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Maravai LifeSciences Holdings's repurchase of stock for the three months ended in Sep. 2024 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Maravai LifeSciences Holdings's net issuance of debt for the three months ended in Sep. 2024 was $-1.5 Mil. Maravai LifeSciences Holdings spent $1.5 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Maravai LifeSciences Holdings's net issuance of preferred for the three months ended in Sep. 2024 was $0.0 Mil. Maravai LifeSciences Holdings paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Maravai LifeSciences Holdings's cash flow for dividends for the three months ended in Sep. 2024 was $0.0 Mil. Maravai LifeSciences Holdings received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Maravai LifeSciences Holdings's other financing for the three months ended in Sep. 2024 was $2.3 Mil. Maravai LifeSciences Holdings received $2.3 Mil on other financial activities.

Maravai LifeSciences Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Executives

John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Carl Hull	director, officer: Chief Executive Officer	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gtcr Investment Xi Llc	director, 10 percent owner	300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Rebecca Buzzeo	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii	officer: See remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy	officer: See Remarks	1620 FARADAY AVE, CARLSBAD CA 92008
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack	officer: General Counsel	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Benjamin James Daverman	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654